Pharmaceutical-manufacturing, Biotechnology, Life Sciences, and Pharmaceutical Facilities and business opportunities available for sale.
Completed Transactions

Completed Transactions

Please find below a sampling of available Biotechnology, Life Sciences, and Pharmaceutical Facilities we have transacted in the past. If you would like to learn more about these transactions or would like to discuss our services, please don’t hesitate to contact us at info@pharmabiosource.com or phone us at 610.293.0900.
Facility Type Location Site Description
Biologics Manufacturing
Krems, Austria 340,000 SF utility-ready pharma / biologics manufacturing site sold to Merck Animal Health
Biologics API Manufacturing
Hayward, CA Shire's 52,000 SF mammalian cell culture manufacturing facility with 3 x 2,000 L single-use bioreactors acquired by Lonza Biologics
Biologics API
Brooklyn Park, MN Baxalta's 215,000 SF mammalian cell culture biologics API manufacturing facility sold to Takeda.
Clinical Packaging
Hauppage, NY Actavis (former Forest Labs) 110,186 SF clinical packaging and warehouse facility located on Long Island, NY sold to Ropack Pharma Solutions.
Solid Dosage Development & Manufacturing
Commack, NY Actavis (former Forest Labs) 103,530 SF solid dosage development and manufacturing facility located on Long Island, NY sold to Ropack Pharma Solutions.
Solid Dosage Manufacturing
Corona, CA Actavis (former Watson Pharmaceuticals) 196,613 SF solid dosage manufacturing facility acquired by Bristol Youcare.
Solid Dosage Packaging
Corona, CA Actavis (former Watson Pharmaceuticals) 285,433 SF solid dosage packaging facility acquired by Bristol Youcare.
Biologics Manufacturing
West Lebanon, NH Olympus Biotech's 180,000 SF mammaliam cell culture manufacturing facility sold to Novo Nordisk.
API Development & Manufacturing
Andover, MA Eisai's 60,000 SF API development and manufacturing facility sold to Sarepta Therapeutics.
Solids and Semi-Solids Manufacturing
Bristol, TN 400,000 SF Pfizer oral and semi-solid dosage form manufacturing facility for tablets, capsules and creams / ointments with controlled substances capabilities.
Oral Dosage Manufacturing
Caguas, Puerto Rico 475,000 SF Pfizer oral dosage manufacturing operation with high containment and controlled substances capabilities, contracts and staff sold to Neolpharma.
Biologics Manufacturing
Brooklyn Park, MN Genmab's 215,000 SF facility with 22,000L of mammalian cell culture capacity sold to Baxter Biosciences.
Parenteral Manufacturing
Rochester, MI King Pharmaceuticals parenteral manufacturing business with 12 branded generic hospital products sold to JHP Pharmaceuticals.
Biologics Manufacturing
Pearl River, NY Leased 78,000 SF of Pfizer’s biologics manufacturing facility to Protein Sciences.
API Manufacturing & Dosage Form
Morpeth, UK Pfizer's 500,000 SF multi-product, multi-use development and manufacturing campus with staff and contracts sold to Nicholas Piramal.
Solid Dosage Manufacturing
Dorado, Puerto Rico Biovail's 175,000 SF solid dosage manufacturing operation sold to Blu Pharmaceuticals.
Liquids & Creams Manufacturing
Lakewood, NJ Subleased 221,000 SF of DPT Labs liquids and creams manufacturing facility to Accupac.
Solid Dosage Manufacturing
Carolina, Puerto Rico AstraZeneca's 80,000 SF solid dosage manufacturing facility.
Biologics Manufacturing
Horsham, PA 50,000 SF Neose GMP pilot plant with preclinical, Phase I and Phase II capability to 2,000L.
Sterile Manufacturing Facility
Miami, FL Teva's 90,000 SF sterile manufacturing facility with associated lab and warehouse acquired by Becton Dickinson.
Biologics Pilot Plant
Piscataway, NJ Subleased 30,000 SF of Enzon’s biologics pilot plant and process development laboratories to Axcellerate Pharma.
Biotech Research Labs
Cambridge, MA Leased 40,000 SF of Draper Labs’ biotech laboratories to Percivia, a joint venture between DSM and Crucell.
Biologics and Patch Manufacturing
Gaithersburg, MD Leased 54,000 SF microbial fermentation and patch manufacturing facility.
API Manufacturing
Southeast US 500,000 SF on over 1,000 acres with three API plants.
Parenteral Manufacturing
Eastern Europe 127,000 SF parenteral and semi-solids manufacturing facility with staff and some contracts.
Sterile Manufacturing
Mid-Atlantic US 25,000 SF ophthalmics manufacturing facility with equipment as well as some staff and contract opportunities.
Sterile Manufacturing
Southeast US 60,000 SF parenteral manufacturing facility with equipment.
Biologics R&D Facility
Northeast US 44,000 SF state-of-the-art biologics R&D facility.
Chemical Manufacturing
Southeast US Significant API site available as ongoing concern with staff and some contracts.
R&D Campus
Europe 300,000 SF clinical trial, R&D and pilot facilities for small molecule drug development and launch.
Parenteral Manufacturing
Northeast US 200,000 SF multi-product manufacturing facility. With equipment, staff and some contracts.
Oral Dosage Form Development
Mid-Atlantic US Oral dosage form development and small scale commercial CRO / CMO operation with contracts and staff.
R&D
Northeast US 130,000 SF research lab facility built in 1992 with multi-function pilot plant with expansion capability on 17 acres.